TBBK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TBBK just sold off sharply (-15.72% regular session; 58 post-market) and the technical trend remains bearish (negative, expanding MACD). While the stock is near support (57.8–61.1) and very oversold (RSI-6 ~26), there is no proprietary buy signal (AI Stock Picker/SwingMax both show no signal) to justify an impatient entry during a downswing. The better decision right now is to hold off rather than buy into a falling trend.
Price/Trend: Sharp breakdown on the day (-15.72% regular), indicating a strong downside impulse. Momentum: MACD histogram -0.712 and negatively expanding = bearish momentum still strengthening. RSI: RSI(6) ~26.3 = oversold conditions, which can produce short-term bounces, but oversold alone is not a reliable ‘buy now’ trigger when MACD is still deteriorating. Moving averages: Converging MAs suggest transition/instability rather than a clean uptrend. Key levels: Support S1 ~61.12 has been lost; price is pressing near S2 ~57.81 (post-market ~58). Resistance/pivot overhead near ~66.49 then ~71.85. Pattern/forecast: Similar-pattern stats suggest limited upside near-term (next day ~+1.2% odds 50/50) and slightly negative bias over the next month (-1.68%).
Intellectia Proprietary Trading Signals
Management actions: Announced/indicated sizable share repurchase plans (reported repurchases ~$150M and plan to repurchase $200M), which can support the stock after large dips.
Guidance: Projected 2026 EPS of ~$5.90 (per news summary) can anchor longer-term confidence if delivered.
Operational positives: Net loans up ~16% to $7.12B and non-interest income rising to 46.7% of total revenue (diversification tailwind).
Earnings event: Q4 2025 EPS of $1.28 missed expectations by ~$0.14, which likely triggered the sharp selloff.
Revenue: Q4 revenue down ~0.7% YoY to ~$128M (per news), reinforcing concerns about near-term growth/earnings quality.
Technical damage: Big gap/selloff with bearish MACD expansion increases the odds of follow-through selling or at least choppy basing before recovery.
Latest provided financial snapshot (2025/Q3): Revenue $168.114M (+38.65% YoY), Net Income $54.927M (+6.62% YoY), EPS $1.18 (+13.46% YoY) — strong top-line growth with steadier bottom-line expansion. Most recent quarter discussed in news (Q4 2025): EPS $1.28 (YoY up ~11% per summary) but below expectations; revenue ~$128M (-0.7% YoY). Net/net: growth exists, but the latest quarter’s miss and revenue softness are currently dominating price action.
No analyst rating/price target change data was provided. From a ‘Wall Street pros/cons’ lens based on available information: Pros would likely emphasize buybacks, loan growth, and 2026 EPS outlook; cons would focus on the Q4 EPS miss, revenue decline, and the severity of the post-earnings selloff that can prompt near-term de-risking.
